Neogenomics (NEO) Gross Margin (2010 - 2026)

Neogenomics has reported Gross Margin for 17 years, with the latest figure at 43.32% in Q1 2026.

• For the quarter ending Q1 2026, Gross Margin fell 27.0% year-over-year to 43.32%; the trailing twelve-month figure through Mar 2026 stood at 43.15% (down 115.0% YoY), and the FY2025 full-year result was 43.21%, down 71.0% from the prior year.
• Gross Margin for Q1 2026 stood at 43.32%, down from 43.83% in the prior quarter.
• The five-year high for Gross Margin was 44.92% in Q4 2024, with the low at 32.63% in Q1 2022.
• Historically, Gross Margin has averaged 41.39% across 5 years, with a median of 42.61% in 2025.
• Annual changes were most pronounced in 2022 — Gross Margin sank 840 bps — and 2023, when it soared 732 bps.
• Neogenomics' Gross Margin stood at 40.97% in 2022, then grew by 6 bps to 43.45% in 2023, then advanced by 3 bps to 44.92% in 2024, then dropped by 2 bps to 43.83% in 2025, then slipped by 1 bps to 43.32% in 2026.
• The last three Gross Margin figures came in at 43.32% (Q1 2026), 43.83% (Q4 2025), and 42.84% (Q3 2025), per Business Quant data.